Table 2.
Number and costs of diagnostic studies within the diagnostic period and within the first 12 months
| Disease group | LVV (n = 141) | AAV (n = 112) | IgAV (n = 64) | p valueA |
|---|---|---|---|---|
| Diagnostic period, days, median (IQR) | 5.0 (13) | 22.5 (38) | 9.5 (25) | < 0.001a,b,c |
| Laboratory tests, n, median (IQR) | 34.0 (35) | 85.5 (96) | 48.0 (56) | < 0.001a,c |
| Laboratory costs, €, median (IQR) | 242.5 (432.9) | 1024.9 (1049.6) | 547.0 (755.3) | < 0.001a,b,c |
| Radiology tests, n, median (IQR) | 2.0 (3) | 4.0 (4) | 1.5 (2) | < 0.001a,c |
| Radiology costs, €, median (IQR) | 189.0 (451) | 357.0 (657) | 76.0 (185) | < 0.001a,c |
| Total costs, €, median (IQR) | 3123.0 (4517.3) | 6754.5 (8812.9) | 3346.1 (6371.5) | < 0.001a,c |
| 12-month period | ||||
| Laboratory tests, n, median (IQR) | 125.0 (82) | 312.0 (246) | 169.5 (224) | < 0.001a,b,c |
| Laboratory costs, €, median (IQR) | 662.0 (651.2) | 2764.1 (2193.1) | 1590.5 (1867.8) | < 0.001a,b,c |
| Radiology tests, n, median (IQR) | 4.0 (5) | 10.0 (9) | 6.0 (8) | < 0.001a,b,c |
| Radiology costs, €, median (IQR) | 520.0 (1206) | 1330.1 (2030) | 554.5 (1191) | < 0.001a,c |
| Total costs, €, median (IQR) | 6605.2 (7681.1) | 16,169.5 (19,193.6) | 10,049.4 (15,137.8) | < 0.001a,b,c |
LVV large-vessel vasculitis, AAV antineutrophil cytoplasmic antibody-associated vasculitis, IgAV IgA vasculitis and other small-vessel vasculitis
Diagnostic period: timeline between the first contact with the tertiary health care and the date of vasculitis diagnosis
12 months after the first contact with the tertiary health care
Ap value across the all groups. Significant values expressed between the groups: aLVV vs. AAV, bLVV vs. IgAV, cAAV vs. IgAV